Physician profile
Cheryl Adkinson
NPI 1013658137
$6,028.65
in general payments reported to CMS, 2019-2025
17 companies · $2,934 in 2025
The $2,934 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $833 · 2024: $2,261 · 2025: $2,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,917 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,917.16 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,247.37 | 2023-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $823.50 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $667.91 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $485.06 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $446.85 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $436.83 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $421.43 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $328.43 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $312.64 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $253.65 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $134.29 | 2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $124.19 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.94 | 2025 | |
| Indivior INC. | $90.43 | 2023-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $66.17 | 2024 | Invega Sustenna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $52.54 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $38.42 | 2023-2024 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Adkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.